NY 101
Alternative Names: NY-101Latest Information Update: 07 Feb 2024
At a glance
- Originator Florida Biotechnologies; University of Miami
- Developer NAYA Biosciences
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Leber's hereditary optic atrophy